

NURSING CHALLENGES CARING FOR BMT PATIENTS WITH GVHD

GVHD

JOYCE NEUMANN PHD, APRN, AOCN, BMTCN

PROGRAM DIRECTOR, SCTCT/ADVANCE PRACTICE NURSE

ADJUVANT ETHICIST, SECTION OF INTEGRATED ETHICS



THE UNIVERSITY OF TEXAS

MDAnderson
~~Cancer~~ Center

Making Cancer History¹®





NURSING (AND MEDICAL) CARE OF BMT PATIENTS IS COMPLICATED !



UNIVERSITY OF TEXAS
MDAnderson
~~Cancer~~ Center

Making Cancer History®

TRENDS IN BMT

- **Survival is improving** and patients are experiencing better quality of life (QOL) during treatment, early recovery and long term.
 - Expanding pool of stem cell sources
 - More effective, less toxic regimens
 - New supportive care drugs
 - Maintenance therapy
 - Specialized medical and nursing care
- Disease recurrence, **Graft-versus-host Disease (GVHD)**, organ failure and secondary cancer common causes of late death



Majhail & Rizzo, 2013; Wingard et al., 2011 (CIBMTR)

THE UNIVERSITY OF TEXAS

MDAnderson
~~Cancer~~ Center

Making Cancer History®

NURSING CONSIDERATIONS

GVHD requires additional set of skills and knowledge: expected and less common side effects, assessment skills, standard and novel treatments, and acute/ICU care.

Effects of acute (late acute or overlapping syndrome) and chronic GVHD:

- **require symptom recognition/knowledge of treatment modalities**
- **management and care of physical & psychosocial elements**
- **require consistent coordination of care for possible prolonged period of time**

Advocating for patient may include preparing for end of life IF refractory to treatment.




THE UNIVERSITY OF TEXAS

**MDAnderson
Cancer Center**

Making Cancer History®

MULTI-DISCIPLINARY GVHD CLINIC



THE UNIVERSITY OF TEXAS

**MDAnderson
Cancer Center**

Making Cancer History®

Nursing care of patients with Skin GVHD


Degree of skin alteration will dictate nursing measures to provide:

- hygiene
 - treatment, topical and systemic
 - infection prevention
 - relief of discomfort
 - functional ability (ADL)
 - body image alterations
- Chronic GVHD Prevention/Early detection: patient education essential.
 - Avoiding sun, use sun protection
 - Skin assessment – regular self and medical exam
 - Recognize risk for skin/oral cancer.



Nursing Care Considerations of Skin GVHD (Neumann, Hymes, Alousi)

Skin Alteration	Topical steroid	Systemic steroids	Cleansing	Dressing	Infection	Moisturize	Pain/discomfort	Functional status/body image
Rash – acute or chronic*	Yes** Acute and non-sclerotic chronic-cream or ointment not lotions	Body surface***	Mild soap – Dove (x contact dermatitis), cetaphil, CeraVe soap	None	Culture suspicious lesions	Yes (esp.after topical steroids Use unscented hypoallergenic cream/ointment,. Aquaphor, CeraVe, Eucerin, Cetaphil, avoid lotions	Pruritis- Sarna, Sarna sensitive (hydrocortisone/ pramoxine), antihistamine, H ₂ blocker. Pain – mild/moderate	Limited ambulation 2 nd to pain, edema Disfigurement –change in appearance 2 nd rash or steroids Provide emotional support for temporary changes
Exfoliative/ Desquamation	+	+(depending on body surface)	Same	None – consider cotton glove/sock after moisturizer applied at night	Culture – antibiotic ointment on open lesion	++	Same	Same
Epidermal denudation/ Moist desquamation/ Ulceration Ulceration area (sclerotic skin)	Avoid open areas	+	Normal saline or sterile water (if using dressing with Ag	Non-adherent with antibiotic ointment / Silver foam (mepilex) /CoolMagic (hydrogel) No adhesive tape/secure w surgiflex/wrap	Culture, if vesicular viral culture to r/o herpes simplex or varicella-zoster	++ (under dressing if non-adherent drsg and intact skin)	Pain – severe, narcotic esp. before dressing change. May need additional med/sedation for more severe pain w drsg changes.	Dependent on location impend ambulation/movement; promote range of motion and/or isometric exercise. Provide emotional support for (temporary) changes
Bullae	+ Area around if needed	+	Mild soap unless broken, then as above	Protective	Same	++ Surrounding intact skin	Above, decompress with sterile needle, if painful.	Above
Sclerotic, hidebound	No	+ Second line tx	Mild soap	No unless with ulceration	Same	+	+ mild to moderate, neuropathy	Prevent contracture- PT, OT, stretching, massage, heat/whirl-pool/support
Dyspigmentation	No	No	Mild soap (Dove, cetaphil)	None	Same	Yes	Referral, cosmetic consideration	None/may be temporary or permanent provide emotional support



ERYTHEMATOUS MACULOPAPULAR RASH (MORBILLIFORM ERUPTION)

- Nikolsky sign









Oral cavity: dryness, ulcers, sclerosis




**Esophagus:
strictures**




**Liver:
Cholestasis**




**G.I. System:
Failure- to- Thrive
Malabsorption**



**Eyes:
dryness,
sicca syndrome**



**Lungs:
Bronchiolitis
obliterans**



**Skin:
Sclerosis
Morphea**

**Vaginal Canal:
Strictures**



**Fascia: Fascitis
Scleroderma**



	SCORE 0	SCORE 1	SCORE 2	SCORE 3
PERFORMANCE SCORE: <div style="border: 1px solid black; width: 50px; height: 20px; margin: 5px 0;"></div> KPS ECOG LPS	<input type="checkbox"/> Asymptomatic and fully active (ECOG 0; KPS or LPS 100%)	<input type="checkbox"/> Symptomatic, fully ambulatory, restricted only in physically strenuous activity (ECOG 1, KPS or LPS 80-90%)	<input type="checkbox"/> Symptomatic, ambulatory, capable of self-care, >50% of waking hours out of bed (ECOG 2, KPS or LPS 60-70%)	<input type="checkbox"/> Symptomatic, limited self-care, >50% of waking hours in bed (ECOG 3-4, KPS or LPS <60%)
SKIN <u>Clinical features:</u> <input type="checkbox"/> Maculopapular rash <input type="checkbox"/> Lichen planus-like features <input type="checkbox"/> Papulosquamous lesions or ichthyosis <input type="checkbox"/> Hyperpigmentation <input type="checkbox"/> Hypopigmentation <input type="checkbox"/> Keratosis pilaris <input type="checkbox"/> Erythema <input type="checkbox"/> Erythroderma <input type="checkbox"/> Poikiloderma <input type="checkbox"/> Sclerotic features <input type="checkbox"/> Pruritus <input type="checkbox"/> Hair involvement <input type="checkbox"/> Nail involvement % BSA involved <div style="border: 1px solid black; width: 50px; height: 20px; margin-left: 10px;"></div>	<input type="checkbox"/> No Symptoms	<input type="checkbox"/> <18% BSA with disease signs but NO sclerotic features	<input type="checkbox"/> 19-50% BSA OR involvement with superficial sclerotic features "not hidebound" (able to pinch)	<input type="checkbox"/> >50% BSA OR deep sclerotic features "hidebound" (unable to pinch) OR impaired mobility, ulceration or severe pruritus


NIH consensus scoring

MOUTH	<input type="checkbox"/> No symptoms	<input type="checkbox"/> Mild symptoms with disease signs but not limiting oral intake significantly	<input type="checkbox"/> Moderate symptoms with disease signs with partial limitation of oral intake	<input type="checkbox"/> Severe symptoms with disease signs on examination with major limitation of oral intake
EYES	<input type="checkbox"/> No symptoms	<input type="checkbox"/> Mild dry eye symptoms not	<input type="checkbox"/> Moderate dry eye symptoms	<input type="checkbox"/> Severe dry eye symptoms



SUBCUTANEOUS SCLEROSIS- CELLULITE-LIKE RIPPLING



Mouth 	Mucosal change	No evidence of cGVHD		Mild		Moderate		Severe	
	Erythema	None	0	Mild erythema or moderate erythema (<25%)	1	Moderate (≥25%) or severe erythema (<25%)	2	Severe erythema (≥25%)	3
	Lichenoid	None	0	Hyperkeratotic changes (<25%)	1	Hyperkeratotic changes (25%-50%)	2	Hyperkeratotic changes (>50%)	3
	Ulcers	None	0	None	0	Ulcers involving ≤20%	3	Severe ulcers (>20%)	6
	Mucocoeles*	None	0	1-5 mucocoeles	1	5-10 mucocoeles	2	Over 10 mucocoeles	3
				*Mucocoeles scored for lower labial and soft palate only			Total score for all mucosal changes		







FIGURE 3. Boston Foundation for Sight PROSE (Prosthetic Replacement of the Ocular Surface Ecosystem) Scleral Lenses

DRESSING

Mepilex Ag Foam
Dressing w/silver,
4" X 4"

Mepilex
border
adhesive
foam



PolyMem Foam Dressing 3" x
3" Non-Adhesive Pink Pads

hydrophilic polyurethane membrane matrix with a
semi-permeable polyurethane continuous thin film
backing



NURSING CONSIDERATION OF GI – GVHD

- Accurate **Intake and output** – **measuring stool volume is essential**, cramping, nocturnal defecation, incontinence.
- **Culture stool** for c. diff, virus (rotavirus, norovirus, adenovirus), parasitic infections.
- Correct **fluid and electrolyte imbalance**, **nutrition** consult
- Administer **treatment**: steroid, antidiarrheal (ATC), antispasmodic, pain medication as needed
- **Skin care** – peri-anal barrier, consider bowel management system (Zassi) if needed for incontinence, bedridden.

COMPLICATIONS OF GVHD TREATMENT

Monitor for treatment adverse effects

- Infectious complications

- Microvascular damage

- Renal

- Steroid myopathy

Physical therapy/occupational consult

Endocrine consult – diabetic nursing educator


- Topical management

Psychosocial – body image

PSYCHOSOCIAL & SEXUAL FUNCTION

- Fatigue/mobility issues/cognitive alteration
- Sleep disorders
- Body image disturbance
- Anxiety disorders, depression
- Post traumatic stress disorder
- Post traumatic growth- new appreciation for life
- Sexual function- assess (dryness, narrowing), vaginal moisturizer & dilator, referral

Functional Performance (Physical Component SF-36) cGVHD



Mitchell, Leidy, Mooney, Dudley et al.(2010) BMT. 100 pts., mean 42 m. post SCT, 40% denovo, 46% multiple sites, 50% severe, 45% moderate, 5% mild

ETHICAL ISSUES RELATED CARING FOR PATIENTS W GVHD

- Outcome for patient is related to response to treatment for GVHD
- Steroid refractory (progression after ≥ 3 days of (max dose) steroids or no response after 7-14 days) aGVHD increase TRM (70%)
- **Breaking bad news** – start early (cultural differences); living will, medical power of attorney. “Advance care planning prior to your Stem Cell Transplantation” patient education document – GVHD discussed.

ISSUES RELATED CARING FOR BMT PATIENTS W GVHD

- Multi-disciplinary team may experience **burnout, compassion fatigue, and/or moral distress***, low career satisfaction, work-life imbalance
- Importance of **support for patients/family, caregivers, and professional care providers** (each other)

*Neumannn, Burns, et al (2016). Hematopoietic Cell Transplantation Multidisciplinary Care Teams: National Survey of Transplant Provider Burnout, Moral Distress and Career Satisfaction

SURVIVORSHIP


GVHD is a major component in any allogeneic BMT Survivorship Program - cover the continuum of treatment, recovery and beyond.

Nurses (and primary care providers) in community settings are presented with unique challenges as more BMT survivors transition from the BMT centers to the community.

BMT SURVIVORSHIP ALGORITHM

Survivorship – Stem Cell Transplantation and Cellular Therapy (SCTCT): Allogeneic Stem Cell Transplant

This practice algorithm has been specifically developed for M. D. Anderson using a multidisciplinary approach and taking into consideration circumstances particular to M. D. Anderson, including the following: M. D. Anderson's specific patient population; M. D. Anderson's services and structure; and M. D. Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.




¹ Qualitative Immunoglobulins include: IgG, IgA, IgM

² Immunodeficiency Profile: CD3, CD4, CD8, CD19, C56

RESOURCES FOR NURSES & PATIENTS

- National Marrow Donor Program /Be The Match
 - bethematchclinical.org
 - Post Transplant Care Guidelines
 - 6, 12, and 24 month post-BMT follow up guidelines in print & electronic format
 - Advances e-newsletter
 - Stay up to date on current research




RESOURCES FOR NURSES & PATIENTS

- www.bmtinfonet.org
- BeTheMatch.org
- www.cancer.org
- www.cancer.gov
- CIBMTR.org
- www.cancercare.org
- www.fertilehope.org
- www.lls.org
- www.nbmtlink.org
- www.oncofertility.northwestern.edu/
- www.resolve.org
- www.resolve.org
- www.supersibs.org
- www.stupidcancer.com
- www.planetcancer.org
- www.vitaloptions.org
- www.youngsurvival.org

EDUCATION/CERTIFICATION FOR BMT NURSING PRACTICE

- Manual for BMT nursing practice, Oncology Nursing Society
- ONS web-based BMT course
- ASBMT – Nursing Special Interest Group
- Oncology Nursing Certification Corporation (ONCC) – Blood and Marrow Transplantation Certified Nurse (BMTCN)



CONCLUSIONS

Nursing care of BMT patients with GVHD require unique knowledge and skills that go beyond basic nursing care:

Administer medication (IV/oral) including novel targeted therapies

Perform procedure commensurate with training : ECP-extracorporeal photopheresis, skin biopsy (APRN)

Skin/dressing care - specialized

TEACH patient and family on expected care requirements and about their “new normal”

Coordinate care and resource (SW, PT, OT, wound care)

Evaluate effectiveness of treatment: report and document

Assist patient and caregiver to cope with complications and care requirements

Seek opportunities to stay current on new therapies in the ever changing specialty. Seek and apply for special training/certification

Support colleagues and seek assistance when needed to the mitigate “cost of caring” (compassion fatigue, moral distress, burnout)

